SciSparc (SPRC) Convertible Debt (2018 - 2025)

SciSparc (SPRC) posted Convertible Debt of $2.1 million for Q2 2025, up 110.07% sequentially from $993000.0 in Q2 2019.

SciSparc (SPRC) Convertible Debt (2018 - 2025) Analysis & Trends

SciSparc has reported Convertible Debt for 3 years, with the latest figure at $2.1 million in Q2 2025.

Quarterly Convertible Debt changed N/A year-over-year to $2.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.1 million (changed N/A YoY) and the FY2018 annual result came in at $779000.0, changed N/A from the prior year.
Convertible Debt advanced to $2.1 million in Q2 2025 per SPRC's latest filing, from $993000.0 in the prior quarter.
Over five years, Convertible Debt peaked at $2.1 million in Q2 2025 and troughed at $2.1 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	SciSparc	836,385.99	836,385.99	-

Download Data